Symbols

Symbols

Aime

Products

News

Markets

Watchlist

Brokers

News/

Stock/

BFRI

BFRI News

Newswire

09:06

Biofrontera completes Phase 1 study for Ameluz, sets FDA submission for 2026.

18:24

Biofrontera shares surge 19.05% after-hours after filing sNDA for Ameluz-PDT in sBCC with robust Phase 3 trial results.

18:22

Biofrontera shares surge 22.22% after-hours after submitting sNDA for Ameluz-PDT in sBCC treatment with strong Phase 3 data.

09:07

Biofrontera shares surge 14.68% premarket after filing sNDA for Ameluz-PDT in sBCC treatment.

09:06

Biofrontera shares surge 20.83% premarket after filing sNDA for Ameluz-PDT in sBCC with robust Phase 3 trial results.

View More

About BFRI

Charts

--

Sector--

Established Date--

Listing Date--

Exchange--

Full-time Employees--

Fiscal Year Ends--

Website

Security Type--

Office address

Business

Introduction

View More